We evaluated patients with coronary artery disease and LDL-C < @ mg/dl enrolled in the TNT ( Treating to New Targets ) trial , randomly assigned to receive atorvastatin @ mg/day versus @ mg/day and with at least one post-baseline measurement of LDL-C .